Sorafenib plus valproic acid for infant spinal glioblastoma.
about
Molecular diagnostics of gliomas: state of the art.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy.OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing.Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
P2860
Sorafenib plus valproic acid for infant spinal glioblastoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Sorafenib plus valproic acid for infant spinal glioblastoma.
@en
Sorafenib plus valproic acid for infant spinal glioblastoma.
@nl
type
label
Sorafenib plus valproic acid for infant spinal glioblastoma.
@en
Sorafenib plus valproic acid for infant spinal glioblastoma.
@nl
prefLabel
Sorafenib plus valproic acid for infant spinal glioblastoma.
@en
Sorafenib plus valproic acid for infant spinal glioblastoma.
@nl
P2093
P1476
Sorafenib plus valproic acid for infant spinal glioblastoma.
@en
P2093
Andrey Korshunov
Christopher Alan Rokes
Johannes E Wolff
Mark Remke
P304
P356
10.1097/MPH.0B013E3181D74702
P577
2010-08-01T00:00:00Z